Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Barinthus Biotherapeutics ( (BRNS) ) just unveiled an announcement.
Barinthus Biotherapeutics has announced a strategic restructuring plan to prioritize its immune tolerance research and development, resulting in a 65% workforce reduction primarily in the UK. The company aims to extend its cash runway to 2027 by focusing on its U.S. operations and terminating the employment of key executives. This shift underscores Barinthus Bio’s commitment to advancing its immunotherapy platform, with a focus on autoimmune diseases and strategic partnerships for further development of its hepatitis B treatment, VTP-300.
More about Barinthus Biotherapeutics
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company specializing in novel immunotherapeutic candidates aimed at treating autoimmune and chronic infectious diseases. The company’s pipeline includes VTP-1000 for celiac disease and VTP-300 for chronic HBV infection, leveraging proprietary platform technologies.
YTD Price Performance: -8.06%
Average Trading Volume: 51,206
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $45.08M
See more insights into BRNS stock on TipRanks’ Stock Analysis page.
